New hope for back pain: drug trial targets ankylosing spondylitis
NCT ID NCT07237568
First seen Nov 20, 2025 · Last updated May 09, 2026 · Updated 20 times
Summary
This study tests a new drug called LNK01001 for people with active ankylosing spondylitis, a type of arthritis that causes back pain and stiffness. About 352 adults who haven't gotten enough relief from standard anti-inflammatory drugs will receive either LNK01001 or a placebo for 16 weeks, then all will get the drug for 36 more weeks. The goal is to see if the drug improves pain, function, and inflammation better than a placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANKYLOSING SPONDYLITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking Union Medical College Hospital
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.